Editor's Special Episode: Future Directions in MPN Treatment with Dr. Hobbs
The HemOnc Pulse
00:00
Clinical trials to watch in the coming year
Dr. Hobbs lists trials to follow: rusfertide, ropeginterferon approvals, imetelstat, BET inhibitors, next‑gen JAK2 inhibitors, and CALR‑targeted agents.
Play episode from 15:06
Transcript
